REDEFINE 3, CagriSema in people living with obesity and cardiovascular diseases

Trial ID:
IRB-23-8138
Athena Philis-Tsimikas, M.D.
The REDEFINE 3 study is evaluating the investigational use of the combination of cagrilinitide and semaglutide (CagriSema) to help treat obesity and impact cardiovascular risk factors. The overall goal is to investigate the long-term safety of CagriSema on the cardiovascular system.

Inclusion Criteria

Patients must:

  • Have type 2 diabetes and/or chronic kidney disease
    Have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral arterial disease)
    Be 55 years of age or older
    Be living with obesity (BMI = 30 kg/m2)
    Be able to attend regular clinic visits and receive phone calls over a period of 3 years
    Meet all other eligibility criteria

Exclusion Criteria

Patients must not:

  • Be pregnant, breastfeeding or plan to get pregnant during the study period

Additional Info

Participants will be assigned by chance to either CagriSema plus standard of care or placebo (no active medication) plus standard of care. Your chance of getting CagriSema or placebo is the same.

Participants will take one injection once a week. Study participation will last for about 3 years and includes 22 clinic visits with the study doctor or study staff.

Contact Info:

  • Isabel Garcia, RN or Rosario (Cherrie) Rosal, RN
  • Garcia.Maria6@scrippshealth.org or Rosal.Rosario@scrippshealth.org
  • 858-309-2602 or 858-336-4314